Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crocs, Inc. (CROX) vs Tilray Brands Inc (TLRY) Price & Performance

Crocs, Inc.Trade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Crocs, Inc. vs Tilray Brands Inc — how do they compare? Crocs, Inc. trades at $131.17 (market cap $6.52B), while Tilray Brands Inc trades at $4.4 (market cap $540.74M). The key difference: Crocs, Inc. is far larger — about 12.1× Tilray Brands Inc's market cap, and Crocs, Inc. is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.

CROXTLRY
Market Cap
$6.52B$540.74M
Sector
Consumer StaplesHealth
52-Week High
$132.78$21.00
52-Week Low
$73.39$4.31
Enterprise Value
$8.11B$637.89M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crocs, Inc.

Crocs (CROX) trades at $130.46, down 1.75% on the day, with strong technical momentum indicated by bullish moving averages and a potential breakout pattern forming. The company has consistently beaten earnings estimates in recent quarters, though 2025 showed a net loss of $81.20M. Strategic partnerships with LEGO and Disney are driving brand innovation, while international growth, particularly in Asia, provides expansion opportunities.

The stock presents a mixed outlook with bullish analyst sentiment (51% buy ratings) and a $131.29 consensus price target offering modest upside. Key risks include recent profitability challenges, high debt levels, and competitive pressures in the footwear sector. Revenue stability and brand strength support long-term potential, but margin recovery remains critical for sustained growth.

Tilray Brands Inc

TLRY trades at $4.46, up 0.9% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $2.19 billion in 2025, with a negative net income margin of -156.67%, though revenue grew to $821.31 million. Analyst consensus is cautious with 65% hold ratings, and recent news highlights expansion in medical cannabis and new product launches.

The outlook remains challenged by persistent losses and high debt levels, but low valuation ratios like P/S of 0.54 and P/B of 0.35 may attract value investors. Key risks include profitability struggles and regulatory uncertainty, while potential catalysts include international expansion and upcoming earnings on July 28, 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Crocs, Inc.

Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.

Read more on CROX

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY